of intergenerational discounting. CONCLUSIONS: Costeffectiveness analysis will increasingly play an informative role in policy analysis of public health interventions even though it is not clear what discount rate is appropriate in each case. However, especially for programmes characterized by long-term diminished risk of disease, death or sequel avoided, possibility of disease eradication, and substantial intergenerational impact, there are no convincing arguments favouring the use of subjective time preferences when setting official discount rates for application in social project evaluation.
Hoyle M, Anderson R University of Exeter, Exeter, England OBJECTIVES: In cost-effectiveness analysis, we aim to account for all future costs and benefits for all patients who are currently eligible for a new health technology and who will become eligible in the future. METHODS: We adapt the fundamental concept from epidemiology of the incidence and prevalence of a disease to cost-effectiveness analysis. We define the prevalent cohort as those patients eligible to switch from the comparator to the new technology at the time the new technology is introduced. Next, we introduce the concept of multiple future incident cohorts. The incident cohort starting t years in the future consists of those patients who first become eligible for the new technology t years in the future. Currently cost-effectiveness analyses worldwide consider only either the prevalent cohort, the incident cohort in only the first year, or a mixture of the two. RESULTS: On average, patients in the prevalent cohort are older and at a more advanced stage of illness than patients in the incident cohort. If the cost and benefit discount rates differ, we show mathematically that the cost-effectiveness of all technologies will be substantially affected by our method. Otherwise, the incremental cost-effectiveness ratio will not change for acute conditions, but may change substantially for chronic conditions, particularly for chronic progressive conditions. CONCLUSIONS: We suggest that analyses capture the costs and benefits arising from the prevalent cohort and all future incident cohorts. If our method had been used in the past, some health technologies would have appeared substantially more cost-effective, others substantially less cost-effective. If possible, parameter values (e.g. average age, disease severity) for both the incident and prevalent cohorts should be obtained from the literature. Otherwise, we describe how such parameters can be estimated.
PMC11 IMPROVING PROBABILISTIC SENSITIVITY ANALYSIS (PSA) IN THE TREATMENT OF UNCERTAINTY COSTS USING MCMC
Monleon-Getino A 1 , Crespo C 2 , Rodriguez Barrios JM 3 , Ocaña J 1 1 University of Barcelona, Barcelona, Spain, 2 Oblikue Consulting, Barcelona, Spain, 3 Medtronic Iberia, Madrid, Spain OBJECTIVES: Economic evaluation(EE) incorporate some degree of uncertainty and variability that arises in a number of ways. Uncertainty represents lack of perfect knowledge on the part of the analyst and may be reduced by further measurement and variability represents heterogeneity or diversity in a population that is irreducible by additional measurements (Spanishguidelines proposal). This paper tries to shed light on the need to separate uncertainty and variability in the EE. METHODS: We propose the Probabilistic Sensitivity Analysis (PSA) as an efficient methodology to treat uncertainty associated to the model "inputs". In PSA, a single variable (or subset of variables) is allowed to vary within its specified probability distribution, and repeat-run sampling-based simulations are performed to produce a weighted distribution of output estimates. It is proposed a bayesian estimation of the results of a target parameter Data] subsequently to PSA as an improvement of the method. We propose calculating the Bayesian interval of probability (BIP) [q|a,b] of the costs associated with treatment during the PSA calculations(it has been assumed that [q|a,b] ª Beta(a,b)[UNKNOWN NODETYPE 9]), defined as those that have an interval probability "high" to contain the parameter; equivalent to frequentist confidence interval P(qmin Յ q Յ qmax) = 1 -a[UNKNOWN NODETYPE 9], using Markov Chains Monte-Carlo but measured as a probability not as confidence (a based). RESULTS: We have studied different scripts using WinBugs and FirstBayes packages for calculating of the estimated costs BIP in a PSA, simulating highly skewed distributions of costs. The separation of uncertainty and variability can affect the study results and policy-making decisions in a non-negligible manner and the best methodology to treat the uncertainty is PSA. CONCLUSIONS: Furthermore this paper is a brief introduction to the decision models, their relation to Bayesian decision theory, and the tools typically used to describe the uncertainties involved presenting an improvement in the PSA using a BIP of the estimated parameters as a robust method. Decision-making about resource allocation for guideline implementation to change clinical practice is inevitably undertaken in a context of uncertainty surrounding the cost-effectiveness of both clinical guidelines and implementation strategies. Recently, a model has been developed in which monetary values are assigned to health outcomes and economic evidence on guidelines and strategies is combined with information on clinical practice to determine the scope of cost-effective guideline implementation. Adopting a net benefit approach, the model overcomes problems with the use of combined ratio statistics when analyzing decision uncertainty concerning clinical practice change. OBJECTIVES: The stochastic application of the model is demonstrated for informing decision-making about the adoption of an audit and feedback strategy for implementing a guideline recommending intensive blood glucose control in type 2 diabetes in primary care in The Netherlands. METHODS: An integrated Bayesian approach to decision modelling and evidence synthesis is adopted using Markov Chain Monte Carlo simulation in WinBUGs. Data on model parameters is gathered from various sources, with the effectiveness of audit and feedback being estimated using a pooled, random effects meta-analysis model. Decision uncertainty is illustrated using cost-effectiveness acceptability curves (CEACs) and frontier (CEAF). RESULTS: Decisions about whether to adopt the guidance on blood glucose control and whether to adopt audit and feedback for its implementation alter over the range of maximum values that decisionmakers are willing to pay for health gain. Through simultaneously incorporating uncertain economic evidence on both guidance and implementation strategy, the CEACs and CEAF show an increase in decision uncertainty concerning guideline implementation. CONCLUSIONS: The stochastic application in diabetes care demonstrates that the model provides a simple and useful tool for quantifying and exploring the (combined) uncertainty associated with decision-making about adopting guidelines and implementation strategies and, therefore, for informing decisions about efficient resource allocation to change clinical practice. Log transformations are frequently used to overcome these problems. Linear regression models (OLS) are then applied to the transformed data. The estimated model coefficients are retransformed back to the linear scale using the smearing approach. Implementing this approach in statistical packages requires customized programming. We propose an alternative to using log transformations: Generalized Linear Models (GLM) with a log link function. We compare the performance of both models in estimating cost-of-illness. METHODS: We derived data from a large administrative database representing 143,593 discharges from 39 US hospitals from January 2004 to December 2005. We estimated total medical costs among hospitalized patients attributable to hyponatremia. Using a cross-validation approach, we compared the performance of two models: log transformed OLS with smearing and GLM with a log link function and a normal error distribution. We used the Root Mean Squared Error (RMSE) and the Mean Absolute Error (MAE) to assess model performance. Covariates in both models included patient age, gender, race, geographic region, Deyo-Charlson comorbidity index, primary diagnosis, teaching status of hospital, and admission source. All analyses were contacted using SAS ® . RESULTS: The GLM with log-link and a normal error distribution had both the smallest RMSE (23,688) and MAE (11,304) compared to the log transformed OLS with smearing (24,057 and 11,392, respectively) . Furthermore, by using GLM, there was no need to compute a retransformation estimate, since the log link function relates the response mean to the original scale. CONCLUSIONS: In this cross-validation study, GLM outperformed OLS with smearing. GLM is easier to implement using SAS ® with no need for retransformation estimates. Because of its ease of use and statistical accuracy, GLM is a useful alternative to log-transformed OLS models with smearing, when estimating cost-of-illness.
PMC12 MODELLING THE VALUE FOR MONEY OF CLINICAL PRACTICE CHANGE: A STOCHASTIC APPLICATION IN DIABETES CARE

Hoomans
PMC13 ESTIMATING COST-OF-ILLNESS USING GENERALIZED LINEAR MODELS: AN ALTERNATIVE TO THE
PMC14 A FRAMEWORK FOR REAL-WORLD ECONOMIC EVALUATION BY INCORPORATING IMPLEMENTATION PARAMETERS
Grutters JP 1 , Joore MA 2 1 Maastro Clinic, Maastricht, The Netherlands, 2 University Hospital Maastricht, Maastricht, The Netherlands OBJECTIVES: Reimbursement decisions are often supported by economic evaluations based on randomised controlled trials (RCTs). A problem with RCTs is that they usually deviate from daily practice. Hence, reimbursement decisions are based on perfect-world assessments of cost-effectiveness. In daily practice, the technology is likely to be less cost-effective for instance due to lower compliance. To make real-world reimbursement decisions, factors that potentially influence the cost-effectiveness should be considered. These factors are implementation factors, and stochastic in nature. This study presents a framework that incorporates the implementation of a technology directly into the economic evaluation, thus anticipating on potentially less than perfect implementation. This results in real-world economic evaluations. METHODS: The framework allows for a stepwise consideration of the net benefit (NB) of a technology in different states of the world: 1) perfect-world (NB under perfect implementation); 2) real-world (NB under expected implementation); and 3) improved-world (NB after intervention to improve implementation).
Step 1 tells us whether the technology could be cost-effective.
Step 2 gives us the real world cost-effectiveness. The difference between the NB of step 1 and 2 gives the upper bound of the value of improving implementation.
Step 3 tells us whether it is cost-effective to invest in specific interventions to improve implementation. The implementation factors are stochastic, therefore in each step parameter uncertainty is addressed in probabilistic sensitivity analyses, and the value of reducing uncertainty is examined in value of information analyses. RESULTS: As a case we used a Markov model that examines the cost-effectiveness of direct hearing aid provision versus provision by referral. Two stochastic implementation parameters were incorporated: patient compliance and professional uptake. The upper bound of the value of improving implementation was €50 million (patient compliance), €23 (professional uptake) and €72 million in total. This suggests that implementation interventions may be valuable (results presented at the conference).
METHODS: CONCLUSIONS:
This framework allows for realword economic evaluations to inform policy decisions. The institute for Medical Technology Assessment, Rotterdam, The Netherlands, 3 The University of Sheffield, Sheffield, South Yorkshire, UK In 1996 the Washington Panel controversially recommended valuing productivity costs (PC) in terms of QALYs. While this recommendation was criticised, the Panel's assumption, that respondents in health state valuation (HSV) exercises take income losses into account, could not be countered since there was no evidence regarding what people consider in HSV exercises. If they do consider income losses and if this changes HSV's, then all past economic evaluations that have included PC in the numerator may have double counted these costs. Alternatively, if respondents do not consider income losses then all past economic evaluations that have not included PC in the numerator have failed to account for sizeable societal costs. OBJECTIVES: To recapture the debate surrounding the appropriate method for including PC in health economic evaluations, to identify empirical evidence addressing the assumptions made by the Washington Panel and to recommend a research agenda for the future. METHODS: In this review we first present and discuss the human capital and friction cost approaches for capturing PC. Then, the Washington Panel approach is highlighted and discussed. Next, we identify, outline and critically appraise the existing empirical studies that attempt to address the assumption that respondents to HSV exercises take income effects into account. Finally, we outline a research agenda for the future that will help to determine the most appropriate method for including PC. RESULTS AND CONCLUSIONS: Only six empirical studies were identified. The studies differ substantially in methods and results and drawing general conclusions from them is difficult. Overall, it seems that not explicitly mentioning the inclusion of income will induce a minority of respondents to
PMC15 IN OR OUT? EMPIRICAL EVIDENCE ON INCOME LOSSES IN HEALTH STATE VALUATIONS AND IMPLICATIONS FOR ECONOMIC EVALUATIONS
Tilling
